Compare Citius Pharmaceuticals Inc (CTXR) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Entegris Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Entegris Inc trades at $142.11 (market cap $21.42B). The key difference: Entegris Inc is far larger — about 1463.1× Citius Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.28% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ENTG | |
|---|---|---|
Market Cap | $14.64M | $21.42B |
Sector | Health | Technology |
52-Week High | $1.82 | $184.00 |
52-Week Low | $0.53 | $68.80 |
Enterprise Value | $10.86M | $24.73B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ENTG trades at $136.27, down 6.25% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 78.77 but strong recent earnings beats. Revenue remains stable at $3.2B with improving net margins. Analyst consensus is bullish with a $178.40 price target, representing 31% upside potential. Recent developments include a new CFO appointment and strategic licensing agreements in semiconductor technology.
ENTG presents a compelling growth story in semiconductor materials with AI-driven demand catalysts, though premium valuation and technical weakness create near-term headwinds. The company's positioning in advanced chip manufacturing and consistent earnings performance support long-term upside, while current price levels offer entry opportunity below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
